A Study of the Effect of Lenalidamide on Complex Regional Pain Syndrome Type 1
Multicenter, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Lenalidamide in the Treatment of Complex Regional Pain Syndrome Type1
Lead SponsorMayo Clinic
StatusCompleted No Results Posted
Indication/ConditionComplex Regional Pain Syndrome, Type 1
The purpose of this study is to determine if lenalidomide is a safe and effective treatment for complex regional pain syndrome type 1 (CRPS).
Inclusion Criteria: Age > or = to 18 years Signed consent form A diagnosis of CRPS type I for at least one-year duration with unilateral involvement of a distal limb CRPS pain intensity score at least 4 on an 11-point PI-NRS Measurable sural, median sensory, median motor and peroneal motor nerve conductions Women of childbearing potential must have a negative serum or urine pregnancy test within 7 days of starting the study drug. They must agree to use adequate contraceptive methods not including steroid-based contraceptives. They must also agree to have pregnancy tests every 4 weeks while on the study drug.